Get prompt alerts when information breaks in your shares. Declare your 1-week free trial to StreetInsider Premium here.
J&J veteran Steven Pfanstiel named as Chief Monetary Officer
Lisa Lejuwaan to construct out launch technique as Vice President of Gross sales
RADNOR, Pa.–(BUSINESS WIRE)–
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical firm devoted to the event of progressive therapeutics to deal with uncommon seizure problems, right now introduced the hiring of Steven E. Pfanstiel as Chief Monetary Officer and Lisa Lejuwaan to the newly created place of Vice President of Gross sales. The appointments mirror Marinus’ continued dedication to constructing a robust management crew and its planning for potential commercialization of ganaxolone in CDKL5 deficiency dysfunction (CDD).
“I’m thrilled that Marinus continues to construct and appeal to stellar leaders equivalent to Lisa and Steve, who can be instrumental in positioning the corporate for its subsequent section of progress,” stated Scott Braunstein, M.D., Chief Govt Officer of Marinus Prescription drugs. “Each convey abilities and seasoned experience that may show invaluable as we construct our group and put together for potential business launch.”
Mr. Pfanstiel, has an extended monitor report in life sciences and prescription drugs, supporting the monetary facet of R&D, provide chain, and world commercialization organizations. He brings 16 years of J&J expertise in varied monetary reporting and enterprise help roles and was most just lately Vice President, Finance for LifeScan of Malvern, PA, a world chief in blood glucose monitoring identified for its OneTouch model merchandise for managing diabetes. At LifeScan, he was accountable for a finance crew of over 40 and drove vital value financial savings whereas optimizing funding in gross sales and advertising and marketing.
Ms. Lejuwaan brings an in depth background in pharmaceutical and biotech gross sales, with a selected experience in launching therapies for uncommon neurological problems. She was most just lately Govt Gross sales Director, Neurology Franchise at Alexion Prescription drugs, the place she managed a gross sales crew of 56 and was accountable for creation and execution of the general business plan in Alexion’s neurology enterprise unit.
“Marinus is dedicated to creating a major distinction within the lives of individuals touched by uncommon pediatric and refractory epilepsy,” stated Steven Pfanstiel. “The science is powerful, and I’m happy to convey a robust monetary self-discipline and basis to help the corporate in its continued improvement actions and because it plans for commercialization of ganaxolone.”
“I’ve seen first-hand the importance a brand new remedy can have for individuals and households affected by uncommon neurological problems,” stated Lisa Lejuwaan. “Ganaxolone holds promise for uncommon pediatric and refractory epilepsy, and I’m honored for the chance to construct the technique and business launch plan for ganaxolone and make a distinction within the lives of those sufferers.”
Steven Pfanstiel, Chief Monetary Officer
Previous to LifeScan, Mr. Pfanstiel held monetary management roles in a variety of life sciences and pharmaceutical organizations, together with Senior Director, Monetary Planning and Evaluation (FP&A) at Optinose; Senior Director, World Strategic Advertising, at Depuy Synthes (Johnson & Johnson); Senior Director, North America Business, Worldwide Monetary Reporting, and Portfolio for LifeScan & Animas (Johnson & Johnson). Previous to his roles with LifeScan and Optinose, Mr. Pfanstiel labored for 16 years in varied divisions and working corporations of Johnson & Johnson.
Mr. Pfanstiel holds a B.A. in Physics from Wabash Faculty in Crawfordsville, IN; an M.S. in Environmental Techniques Engineering from Clemson College in Clemson, SC; and an M.B.A. in Finance from the Indiana College Kelley Faculty of Enterprise in Indianapolis, IN.
Lisa Lejuwaan, Vice President of Gross sales
Lisa Lejuwaan has over 25 years of pharmaceutical gross sales and gross sales management expertise. She joined Alexion Prescription drugs in 2014 as an account supervisor for the Atlanta area, rapidly transferring into gross sales management in Alexion’s neurological franchise, first as Enterprise Director after which as Govt Gross sales Director. There, she managed gross sales in two neurological uncommon ailments, generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Dysfunction, rising gMG to be the biggest total driver of income throughout Alexion.
Previous to Alexion, Ms. Lejuwaan labored for 13 years with Sanofi Genzyme in quite a lot of gross sales, area advertising and marketing and gross sales management roles for surgical units and endocrine therapies. She has additionally held gross sales positions in Galena Biopharma, Sankyo Parke Davis, Abbott Laboratories, Mark Clark Medical Provides, and Astra Prescription drugs.
Ms. Lejuwaan holds a B.A. in Political Science and Worldwide Enterprise from Kansas State College, Manhattan, KS, the place she graduated with honors and is a member of the Phi Beta Kappa and Golden Key honor societies.
About Marinus Prescription drugs
Marinus Prescription drugs, Inc. is a pharmaceutical firm devoted to the event of progressive therapeutics to deal with uncommon seizure problems. Ganaxolone is a constructive allosteric modulator of GABAA receptors that acts on a well-characterized goal within the mind identified to have anti-seizure, antidepressant and anti-anxiety results. Ganaxolone is being developed in IV and oral dose formulations meant to maximise therapeutic attain to grownup and pediatric affected person populations in each acute and continual care settings. Marinus just lately accomplished the primary ever Section 3 pivotal trial in kids with CDKL5 deficiency dysfunction, is conducting a Section 2 trial in tuberous sclerosis complicated, and has just lately disclosed prime line outcomes from its Section 2 proof-of-concept trial in PCDH19-related epilepsy. The corporate has initiated a Section 3 trial in refractory standing epilepticus. For extra info go to www.marinuspharma.com.
To the extent that statements contained on this press launch will not be descriptions of historic information concerning Marinus, they’re forward-looking statements reflecting the present beliefs and expectations of administration made pursuant to the secure harbor provisions of the Non-public Securities Litigation Reform Act of 1995. Phrases equivalent to “might”, “will”, “anticipate”, “anticipate”, “estimate”, “intend”, “imagine”, and comparable expressions (in addition to different phrases or expressions referencing future occasions, situations or circumstances) are meant to determine forward-looking statements. Examples of forward-looking statements contained on this press launch embrace, amongst others, statements concerning our medical improvement plans for ganaxolone; our expectations concerning submission of a brand new drug software to FDA to be used of ganaxolone in CDLK5 Deficiency Dysfunction (CDD); our plans to commercialize ganaxolone in CDD; our expectations that our money, money equivalents and investments can be adequate to fund our working bills and capital expenditures into 2022; the potential security and efficacy of ganaxolone; and the therapeutic potential of ganaxolone. Ahead-looking statements on this press launch contain substantial dangers and uncertainties that would trigger our medical improvement packages, future outcomes, efficiency or achievements to vary considerably from these expressed or implied by the forward-looking statements. Such dangers and uncertainties embrace, amongst others, uncertainties referring to the power to acquire FDA approval of the usage of ganaxolone in CDD; actions or recommendation of the U.S. Meals and Drug Administration might have an effect on the design, initiation, timing, continuation and/or progress of medical trials or consequence within the want for extra medical trials; our means to acquire and preserve regulatory approval for our product candidate; medical trial outcomes might not help regulatory approval or additional improvement in a specified indication or in any respect; uncertainties and delays associated to the design, enrollment, completion, and outcomes of medical trials; unanticipated prices and bills; early medical trials is probably not indicative of the leads to later medical trials; our means to acquire and preserve patent safety for our product candidates; the impression of third get together patents; delays, interruptions or failures within the manufacture and provide of our product candidate; our means to boost extra capital; the impact of the COVID-19 pandemic on our enterprise, the medical neighborhood and the worldwide financial system; and the provision or potential availability of other merchandise or remedies for situations focused by us that would have an effect on the provision or business potential of our product candidate. Marinus undertakes no obligation to replace or revise any forward-looking statements. For an additional description of the dangers and uncertainties that would trigger precise outcomes to vary from these expressed in these forward-looking statements, in addition to dangers referring to the enterprise of the corporate on the whole, see filings Marinus has made with the Securities and Trade Fee.
Sasha Damouni Ellis
Vice President, Investor Relations & Company Communications
Marinus Prescription drugs, Inc.
Supply: Marinus Prescription drugs